CDCP1 and cancer: Analysis of pre-clinical models and patient samples indicate that CDCP1 promotes metastasis and chemotherapeutic resistance in a range of cancers 8-11, 14-16, 30, 39, 40, and this cell surface protein has been proposed as a target for antibody-based therapy for several malignancies 6, 9-11, 19-21, 24.